David Budd, Chief Executive Officer of genedrive plc said: “This has the opportunity to be a very novel and impactful project and we are delighted that Innovate UK has chosen to support us. This device will aim to improve the applicability of the Genedrive® HCV assay for closer to patient settings and would be a significant step forward in positioning the test for true decentralised diagnostics. Further, the device is anticipated to be independent from the Genedrive® platform, opening the opportunity for other diagnostic instruments that need plasma as a starting point for blood borne viral testing.”
Genedrive®HCV ID Kit is performed on the Company’s Genedrive® portable molecular diagnostics platform, designed for use at the point of need. The assay uses only a small amount of human plasma (25ul), eliminating the need for a separate RNA viral extraction process, and yields results within 90 minutes. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.
